Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

1.

High ABCC2 and Low ABCG2 Gene Expression Are Early Events in the Colorectal Adenoma-Carcinoma Sequence.

Andersen V, Vogel LK, Kopp TI, Sæbø M, Nonboe AW, Hamfjord J, Kure EH, Vogel U.

PLoS One. 2015 Mar 20;10(3):e0119255. doi: 10.1371/journal.pone.0119255. eCollection 2015.

2.

Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas.

Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH.

Mol Oncol. 2014 Dec 19. pii: S1574-7891(14)00287-7. doi: 10.1016/j.molonc.2014.12.002. [Epub ahead of print]

PMID:
25579086
3.

Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.

Vogel LK, Sæbø M, Høyer H, Kopp TI, Vogel U, Godiksen S, Frenzel FB, Hamfjord J, Bowitz-Lothe IM, Johnson E, Kure EH, Andersen V.

PLoS One. 2014 Aug 28;9(8):e105254. doi: 10.1371/journal.pone.0105254. eCollection 2014.

4.

Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines.

Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E.

PLoS One. 2014 Aug 22;9(8):e103873. doi: 10.1371/journal.pone.0103873. eCollection 2014.

5.

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.

Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH.

BMC Cancer. 2014 May 19;14:340. doi: 10.1186/1471-2407-14-340.

6.

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM.

PLoS One. 2014 Feb 3;9(2):e87746. doi: 10.1371/journal.pone.0087746. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98836.

7.

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH.

Mol Oncol. 2014 Feb;8(1):59-67. doi: 10.1016/j.molonc.2013.09.001. Epub 2013 Sep 21.

PMID:
24119443
8.

Molecular responses to toxicological stressors: profiling microRNAs in wild Atlantic salmon (Salmo salar) exposed to acidic aluminum-rich water.

Kure EH, Sæbø M, Stangeland AM, Hamfjord J, Hytterød S, Heggenes J, Lydersen E.

Aquat Toxicol. 2013 Aug 15;138-139:98-104. doi: 10.1016/j.aquatox.2013.04.004. Epub 2013 Apr 24.

9.

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.

Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH.

BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534.

10.

KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem.

Kure EH, Hamfjord J, Stangeland AM, Tveit KM, Ikdahl T.

Expert Rev Mol Diagn. 2012 May;12(4):327-8. doi: 10.1586/erm.12.29. No abstract available.

PMID:
22616697
11.

Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing.

Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH.

PLoS One. 2012;7(4):e34150. doi: 10.1371/journal.pone.0034150. Epub 2012 Apr 17.

12.

Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations.

Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH.

Diagn Mol Pathol. 2011 Sep;20(3):158-65. doi: 10.1097/PDM.0b013e31820b49e2.

PMID:
21817902
13.

ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues.

Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA.

Front Biosci (Elite Ed). 2011 Jun 1;3:1443-55.

PMID:
21622148
14.

The level of claudin-7 is reduced as an early event in colorectal carcinogenesis.

Bornholdt J, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC, Lothe IM, Ikdahl T, Tveit KM, Johnson E, Kure EH, Vogel LK.

BMC Cancer. 2011 Feb 10;11:65. doi: 10.1186/1471-2407-11-65.

15.

Influence of GSTM1, GSTT1, GSTP1, NAT1, NAT2, EPHX1, MTR and MTHFR polymorphism on chromosomal aberration frequencies in human lymphocytes.

Skjelbred CF, Svendsen M, Haugan V, Eek AK, Clausen KO, Kure EH, Tuimala JT, Svendsen MV, Norppa H, Hansteen IL.

Carcinogenesis. 2011 Mar;32(3):399-405. doi: 10.1093/carcin/bgq246. Epub 2010 Nov 19.

16.

Cytogenetic effects of exposure to 2.3 GHz radiofrequency radiation on human lymphocytes in vitro.

Hansteen IL, Clausen KO, Haugan V, Svendsen M, Svendsen MV, Eriksen JG, Skiaker R, Hauger E, Lågeide L, Vistnes AI, Kure EH.

Anticancer Res. 2009 Nov;29(11):4323-30.

17.

Cytogenetic effects of 18.0 and 16.5 GHz microwave radiation on human lymphocytes in vitro.

Hansteen IL, Lågeide L, Clausen KO, Haugan V, Svendsen M, Eriksen JG, Skiaker R, Hauger E, Vistnes AI, Kure EH.

Anticancer Res. 2009 Aug;29(8):2885-92.

18.

Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis.

Selzer-Plon J, Bornholdt J, Friis S, Bisgaard HC, Lothe IM, Tveit KM, Kure EH, Vogel U, Vogel LK.

BMC Cancer. 2009 Jun 25;9:201. doi: 10.1186/1471-2407-9-201.

19.

Collagen mRNA levels changes during colorectal cancer carcinogenesis.

Skovbjerg H, Anthonsen D, Lothe IM, Tveit KM, Kure EH, Vogel LK.

BMC Cancer. 2009 May 7;9:136. doi: 10.1186/1471-2407-9-136.

20.

CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas.

Saebø M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH.

Anticancer Res. 2008 Jul-Aug;28(4C):2289-95.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk